## Kyong-Mi Chang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/866892/publications.pdf

Version: 2024-02-01

115 papers 14,039 citations

50170 46 h-index 97 g-index

129 all docs

129 does citations

times ranked

129

17643 citing authors

#	Article	IF	CITATIONS
1	<i>APOL1</i> Risk Variants, Acute Kidney Injury, and Death in Participants With African Ancestry Hospitalized With COVID-19 From the Million Veteran Program. JAMA Internal Medicine, 2022, 182, 386.	2.6	31
2	Coronary Artery Disease Risk of Familial Hypercholesterolemia Genetic Variants Independent of Clinically Observed Longitudinal Cholesterol Exposure. Circulation Genomic and Precision Medicine, 2022, 15, CIRCGEN121003501.	1.6	6
3	259 Proton pump inhibitor use is not significantly associated with severe COVID-19 related outcomes after extensive covariate adjustment. Journal of Clinical and Translational Science, 2022, 6, 43-43.	0.3	O
4	A Phenome-Wide Association Study of genes associated with COVID-19 severity reveals shared genetics with complex diseases in the Million Veteran Program. PLoS Genetics, 2022, 18, e1010113.	1.5	16
5	Genome-wide and phenome-wide analysis of ideal cardiovascular health in the VA Million Veteran Program. PLoS ONE, 2022, 17, e0267900.	1.1	2
6	A multiancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation. Nature Genetics, 2022, 54, 761-771.	9.4	68
7	A multi-population phenome-wide association study of genetically-predicted height in the Million Veteran Program. PLoS Genetics, 2022, 18, e1010193.	1.5	12
8	Multiple Roles for Hepatitis B and C Viruses and the Host in the Development of Hepatocellular Carcinoma. Hepatology, 2021, 73, 27-37.	3.6	23
9	Precore and Basal Core Promoter Hepatitis B Virus (HBV) Variants Are Present From a Young Age and Differ Across HBV Genotypes. Hepatology, 2021, 73, 1637-1651.	3.6	11
10	Actionable druggable genome-wide Mendelian randomization identifies repurposing opportunities for COVID-19. Nature Medicine, 2021, 27, 668-676.	15.2	120
11	Highly multiplexed 2-dimensional imaging mass cytometry analysis of HBV-infected liver. JCI Insight, 2021, 6, .	2.3	15
12	Genetic analysis in European ancestry individuals identifies $517$ loci associated with liver enzymes. Nature Communications, $2021$ , $12$ , $2579$ .	5.8	51
13	Association of the transthyretin variant V122I with polyneuropathy among individuals of African ancestry. Scientific Reports, 2021, 11, 11645.	1.6	15
14	Association Between Genetic Variation in Blood Pressure and Increased Lifetime Risk of Peripheral Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 2027-2034.	1.1	24
15	Genetic Evidence for Repurposing of GLP1R (Glucagonâ€Like Peptideâ€1 Receptor) Agonists to Prevent Heart Failure. Journal of the American Heart Association, 2021, 10, e020331.	1.6	13
16	American Association for the Study of Liver Diseases Expert Panel Consensus Statement: Vaccines to Prevent Coronavirus Disease 2019 Infection in Patients With Liver Disease. Hepatology, 2021, 74, 1049-1064.	3.6	136
17	Prioritizing the Role of Major Lipoproteins and Subfractions as Risk Factors for Peripheral Artery Disease. Circulation, 2021, 144, 353-364.	1.6	47
18	Prospects for the Global Elimination of Hepatitis B. Annual Review of Virology, 2021, 8, 437-458.	3.0	26

#	Article	IF	CITATIONS
19	A Missense Variant in the IL-6 Receptor and Protection From Peripheral Artery Disease. Circulation Research, 2021, 129, 968-970.	2.0	11
20	Genetics of Smoking and Risk of Atherosclerotic Cardiovascular Diseases. JAMA Network Open, 2021, 4, e2034461.	2.8	42
21	Multi-Trait Genome-Wide Association Study of Atherosclerosis Detects Novel Pleiotropic Loci. Frontiers in Genetics, 2021, 12, 787545.	1.1	3
22	The power of genetic diversity in genome-wide association studies of lipids. Nature, 2021, 600, 675-679.	13.7	353
23	Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference‡. Journal of Hepatology, 2020, 72, 539-557.	1.8	208
24	Genetic Architecture of Abdominal Aortic Aneurysm in the Million Veteran Program. Circulation, 2020, 142, 1633-1646.	1.6	78
25	Genetic determinants of increased body mass index mediate the effect of smoking on increased risk for type 2 diabetes but not coronary artery disease. Human Molecular Genetics, 2020, 29, 3327-3337.	1.4	6
26	Validating a non-invasive, ALT-based non-alcoholic fatty liver phenotype in the million veteran program. PLoS ONE, 2020, 15, e0237430.	1.1	15
27	The relationship between circulating lipids and breast cancer risk: A Mendelian randomization study. PLoS Medicine, 2020, 17, e1003302.	3.9	63
28	Discovery of 318 new risk loci for type 2 diabetes and related vascular outcomes among 1.4 million participants in a multi-ancestry meta-analysis. Nature Genetics, 2020, 52, 680-691.	9.4	445
29	Minority-centric meta-analyses of blood lipid levels identify novel loci in the Population Architecture using Genomics and Epidemiology (PAGE) study. PLoS Genetics, 2020, 16, e1008684.	1.5	17
30	Serum alanine aminotransferase flares in chronic hepatitis B infection: the good and the bad. The Lancet Gastroenterology and Hepatology, 2020, 5, 406-417.	3.7	64
31	A missense variant in Mitochondrial Amidoxime Reducing Component $1$ gene and protection against liver disease. PLoS Genetics, 2020, $16$ , e $1008629$ .	1.5	101
32	Cross-trait analyses with migraine reveal widespread pleiotropy and suggest a vascular component to migraine headache. International Journal of Epidemiology, 2020, 49, 1022-1031.	0.9	34
33	PCSK9 loss of function is protective against extra-coronary atherosclerotic cardiovascular disease in a large multi-ethnic cohort. PLoS ONE, 2020, 15, e0239752.	1.1	9
34	Title is missing!. , 2020, 16, e1008684.		0
35	Title is missing!. , 2020, 16, e1008684.		0
36	Title is missing!. , 2020, 16, e1008684.		О

#	Article	IF	CITATIONS
37	Title is missing!. , 2020, 16, e1008684.		O
38	Title is missing!. , 2020, 16, e1008684.		0
39	Title is missing!. , 2020, 16, e1008684.		0
40	The relationship between circulating lipids and breast cancer risk: A Mendelian randomization study. , 2020, $17$ , e $1003302$ .		0
41	The relationship between circulating lipids and breast cancer risk: A Mendelian randomization study. , 2020, 17, e1003302.		0
42	The relationship between circulating lipids and breast cancer risk: A Mendelian randomization study. , 2020, 17, e1003302.		0
43	The relationship between circulating lipids and breast cancer risk: A Mendelian randomization study. , 2020, 17, e1003302.		0
44	The relationship between circulating lipids and breast cancer risk: A Mendelian randomization study. , 2020, 17, e1003302.		0
45	The relationship between circulating lipids and breast cancer risk: A Mendelian randomization study. , 2020, 17, e1003302.		0
46	The relationship between circulating lipids and breast cancer risk: A Mendelian randomization study. , 2020, 17, e1003302.		0
47	Association of <i>APOL1</i> Risk Alleles With Cardiovascular Disease in Blacks in the Million Veteran Program. Circulation, 2019, 140, 1031-1040.	1.6	31
48	Genome-wide association study of peripheral artery disease in the Million Veteran Program. Nature Medicine, 2019, 25, 1274-1279.	15.2	177
49	Long-term use of hydrocodone vs. oxycodone in primary care. Drug and Alcohol Dependence, 2019, 205, 107524.	1.6	5
50	Genome-wide association analysis of venous thromboembolism identifies new risk loci and genetic overlap with arterial vascular disease. Nature Genetics, 2019, 51, 1574-1579.	9.4	152
51	Harmonizing Genetic Ancestry and Self-identified Race/Ethnicity in Genome-wide Association Studies. American Journal of Human Genetics, 2019, 105, 763-772.	2.6	169
52	Multiplexed In Situ Imaging Mass Cytometry Analysis of the Human Endocrine Pancreas and Immune System in Type 1 Diabetes. Cell Metabolism, 2019, 29, 769-783.e4.	7.2	151
53	Distinct phenotype and function of circulating $\hat{VI}$ 1+ and $\hat{VI}$ 2+ $\hat{I}^3\hat{I}$ T-cells in acute and chronic hepatitis B. PLoS Pathogens, 2019, 15, e1007715.	2.1	23
54	Hepatocellular Cancer Induced byÂlnfection. Current Cancer Research, 2019, , 247-259.	0.2	0

#	Article	IF	CITATIONS
55	A global scientific strategy to cure hepatitis B. The Lancet Gastroenterology and Hepatology, 2019, 4, 545-558.	3.7	342
56	Association Between Severe Serum Alanine Aminotransferase Flares and Hepatitis B e Antigen Seroconversion and HBV DNA Decrease in Untreated Patients With Chronic HBV Infection. Clinical Gastroenterology and Hepatology, 2019, 17, 2541-2551.e2.	2.4	28
57	Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology, 2018, 67, 1560-1599.	3.6	2,620
58	Deep immune profiling by mass cytometry links human T and NK cell differentiation and cytotoxic molecule expression patterns. Journal of Immunological Methods, 2018, 453, 3-10.	0.6	64
59	A research agenda for curing chronic hepatitis B virus infection. Hepatology, 2018, 67, 1127-1131.	3.6	70
60	Genetics of blood lipids among ~300,000 multi-ethnic participants of the Million Veteran Program. Nature Genetics, 2018, 50, 1514-1523.	9.4	497
61	Epigenomic-Guided Mass Cytometry Profiling Reveals Disease-Specific Features of Exhausted CD8ÂT Cells. Immunity, 2018, 48, 1029-1045.e5.	6.6	250
62	Reply. Hepatology, 2018, 68, 1658-1660.	3.6	2
63	Predicting short-term interruptions of antiretroviral therapy from summary adherence data: Development and test of a probability model. PLoS ONE, 2018, 13, e0194713.	1.1	6
64	Modulation of Hepatitis C Virus-Specific CD8 Effector T-Cell Function with Antiviral Effect in Infectious Hepatitis C Virus Coculture Model. Journal of Virology, 2017, 91, .	1.5	4
65	AASLD guidelines for treatment of chronic hepatitis B. Hepatology, 2016, 63, 261-283.	3.6	1,662
66	Improved Survival Among all Interferon-α-Treated Patients in HCV-002, a Veterans Affairs Hepatitis C Cohort of 2211 Patients, Despite Increased Cirrhosis Among Nonresponders. Digestive Diseases and Sciences, 2016, 61, 1744-1756.	1.1	3
67	Chronic hepatitis B: immune pathogenesis and emerging immunotherapeutics. Current Opinion in Pharmacology, 2016, 30, 93-105.	1.7	25
68	Single-Cell Mass Cytometry Analysis of the Human Endocrine Pancreas. Cell Metabolism, 2016, 24, 616-626.	7.2	126
69	Evolution in Our Understanding of Hepatitis B Virus Virology and Immunology. Clinics in Liver Disease, 2016, 20, 629-644.	1.0	16
70	Hepatitis B Virus–Specific and Global T-Cell Dysfunction in Chronic Hepatitis B. Gastroenterology, 2016, 150, 684-695.e5.	0.6	178
71	Present and future therapies of hepatitis B: From discovery to cure. Hepatology, 2015, 62, 1893-1908.	3.6	269
72	Prevalence and risk factors for patient-reported joint pain among patients with HIV/Hepatitis C coinfection, Hepatitis C monoinfection, and HIV monoinfection. BMC Musculoskeletal Disorders, 2015, 16, 93.	0.8	12

#	Article	IF	CITATIONS
73	Veterans Affairs Office of Research and Development: Research Programs and Emerging Opportunities in Digestive Diseases Research. Gastroenterology, 2015, 149, 1652-1661.	0.6	10
74	Distinct Features in Natural History and Outcomes of Acute Hepatitis C. Journal of Clinical Gastroenterology, 2015, 49, e31-e40.	1.1	23
75	Characteristics of Adults in the Hepatitis B Research Network in North America Reflect Their Country of Origin and Hepatitis B Virus Genotype. Clinical Gastroenterology and Hepatology, 2015, 13, 183-192.	2.4	90
76	Induction of Multiple Immune Regulatory Pathways with Differential Impact in HCV/HIV Coinfection. Frontiers in Immunology, 2014, 5, 265.	2.2	14
77	Hepatitis C virus: virology and life cycle. Clinical and Molecular Hepatology, 2013, 19, 17.	4.5	134
78	A Randomized, Double-Blind, Placebo-Controlled Assessment of BMS-936558, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients with Chronic Hepatitis C Virus Infection. PLoS ONE, 2013, 8, e63818.	1.1	204
79	Different affinity windows for virus and cancerâ€specific <scp>T</scp> â€cell receptors: Implications for therapeutic strategies. European Journal of Immunology, 2012, 42, 3174-3179.	1.6	212
80	Innate Lymphoid Cells Promote Anatomical Containment of Lymphoid-Resident Commensal Bacteria. Science, 2012, 336, 1321-1325.	6.0	638
81	Dysfunctional B-cell activation in cirrhosis resulting from hepatitis C infection associated with disappearance of CD27-Positive B-cell population. Hepatology, 2012, 55, 709-719.	3 <b>.</b> 6	83
82	Immune Pathogenesis of Viral Hepatitis B and C. , 2012, , 111-128.		1
82	Immune Pathogenesis of Viral Hepatitis B and C., 2012, , 111-128.  Homeostasis of peripheral FoxP3+ CD4+ regulatory T cells in patients with early and late stage breast cancer. Cancer Immunology, Immunotherapy, 2010, 59, 599-607.	2.0	1 35
	Homeostasis of peripheral FoxP3+ CD4+ regulatory T cells in patients with early and late stage breast	2.0	
83	Homeostasis of peripheral FoxP3+ CD4+ regulatory T cells in patients with early and late stage breast cancer. Cancer Immunology, Immunotherapy, 2010, 59, 599-607.		35
83	Homeostasis of peripheral FoxP3+ CD4+ regulatory T cells in patients with early and late stage breast cancer. Cancer Immunology, Immunotherapy, 2010, 59, 599-607.  Hepatitis B and the Immune System. Current Hepatitis Reports, 2010, 9, 205-213.  Hepatitis C Virus Transmission Bottlenecks Analyzed by Deep Sequencing. Journal of Virology, 2010, 84,	0.3	35 O
83 84 85	Homeostasis of peripheral FoxP3+ CD4+ regulatory T cells in patients with early and late stage breast cancer. Cancer Immunology, Immunotherapy, 2010, 59, 599-607.  Hepatitis B and the Immune System. Current Hepatitis Reports, 2010, 9, 205-213.  Hepatitis C Virus Transmission Bottlenecks Analyzed by Deep Sequencing. Journal of Virology, 2010, 84, 6218-6228.	0.3	35 O 135
83 84 85 86	Homeostasis of peripheral FoxP3+ CD4+ regulatory T cells in patients with early and late stage breast cancer. Cancer Immunology, Immunotherapy, 2010, 59, 599-607.  Hepatitis B and the Immune System. Current Hepatitis Reports, 2010, 9, 205-213.  Hepatitis C Virus Transmission Bottlenecks Analyzed by Deep Sequencing. Journal of Virology, 2010, 84, 6218-6228.  Hepatitis B Immunology for Clinicians. Clinics in Liver Disease, 2010, 14, 409-424.  Determinants of in vitro expansion of different human virus-specific FoxP3+ regulatory CD8+ T cells	0.3 1.5 1.0	35 0 135 15
83 84 85 86	Homeostasis of peripheral FoxP3+ CD4+ regulatory T cells in patients with early and late stage breast cancer. Cancer Immunology, Immunotherapy, 2010, 59, 599-607.  Hepatitis B and the Immune System. Current Hepatitis Reports, 2010, 9, 205-213.  Hepatitis C Virus Transmission Bottlenecks Analyzed by Deep Sequencing. Journal of Virology, 2010, 84, 6218-6228.  Hepatitis B Immunology for Clinicians. Clinics in Liver Disease, 2010, 14, 409-424.  Determinants of in vitro expansion of different human virus-specific FoxP3+ regulatory CD8+ T cells in chronic hepatitis C virus infection. Journal of General Virology, 2009, 90, 1692-1701.  Synergistic Reversal of Intrahepatic HCV-Specific CD8 T Cell Exhaustion by Combined PD-1/CTLA-4	0.3 1.5 1.0	35 0 135 15

#	Article	IF	Citations
91	Human leukocyte antigen class II associations with hepatitis C virus clearance and virusâ€specific CD4 T cell response among Caucasians and African Americans. Hepatology, 2008, 48, 70-79.	3.6	52
92	Functional Restoration of HCV-Specific CD8 T Cells by PD-1 Blockade Is Defined by PD-1 Expression and Compartmentalization. Gastroenterology, 2008, 134, 1927-1937.e2.	0.6	263
93	Peripheral virus-specific T-cell interleukin-10 responses develop early in acute hepatitis C infection and become dominant in chronic hepatitis. Journal of Hepatology, 2008, 48, 903-913.	1.8	70
94	Identification and In Vitro Expansion of Functional Antigen-Specific CD25 <sup>+</sup> FoxP3 <sup>+</sup> Regulatory T Cells in Hepatitis C Virus Infection. Journal of Virology, 2008, 82, 5043-5053.	1.5	150
95	Previously Infected Chimpanzees Are Not Consistently Protected against Reinfection or Persistent Infection after Reexposure to the Identical Hepatitis C Virus Strain. Journal of Virology, 2008, 82, 8183-8195.	1.5	81
96	Discordant Role of CD4 T-Cell Response Relative to Neutralizing Antibody and CD8 T-Cell Responses in Acute Hepatitis C. Gastroenterology, 2007, 132, 654-666.	0.6	146
97	Regulatory T cells in hepatitis C virus infection. Hepatology Research, 2007, 37, S327-S330.	1.8	17
98	Current status of vaccine therapy for hepatitis c infection. Current Hepatitis Reports, 2006, 5, 68-74.	0.3	0
99	Racial Difference in Mortality Among U.S. Veterans with HCV/HIV Coinfection. American Journal of Gastroenterology, 2006, 101, 760-767.	0.2	21
100	Regulatory T cells and the liver: A new piece of the puzzle. Hepatology, 2005, 41, 700-702.	3.6	26
101	T-cell response relative to genotype and ethnicity during antiviral therapy for chronic hepatitis C. Hepatology, 2005, 41, 1365-1375.	3.6	53
102	Strain-Specific T-Cell Suppression and Protective Immunity in Patients with Chronic Hepatitis C Virus Infection. Journal of Virology, 2005, 79, 6976-6983.	1.5	43
103	Influence of alcohol use, race, and viral coinfections on spontaneous HCV clearance in a US veteran population. Hepatology, 2004, 40, 892-899.	3.6	72
104	Influence of alcohol use, race, and viral coinfections on spontaneous HCV clearance in a US veteran population. Hepatology, 2004, 40, 892-899.	3.6	35
105	Influence of ethnicity in the outcome of hepatitis C virus infection and cellular immune response. Hepatology, 2003, 37, 590-599.	3.6	102
106	Suppression of HCV-specific T cells without differential hierarchy demonstrated in persistent HCV infection. Hepatology, 2003, 38, 1437-1448.	3.6	199
107	Immunopathogenesis of hepatitis C virus infection. Clinics in Liver Disease, 2003, 7, 89-105.	1.0	84
108	Acute hepatitis C: To treat or not to treat?. Hepatology, 2002, 35, 1538-1540.	3.6	4

#	Article	IF	CITATIONS
109	Determinants of Viral Clearance and Persistence during Acute Hepatitis C Virus Infection. Journal of Experimental Medicine, 2001, 194, 1395-1406.	4.2	1,091
110	Differential CD4+ and CD8+ T-cell responsiveness in hepatitis C virus infection. Hepatology, 2001, 33, 267-276.	3.6	316
111	Degenerate Immunogenicity of an HLA-A2-Restricted Hepatitis B Virus Nucleocapsid Cytotoxic T-Lymphocyte Epitope That Is Also Presented by HLA-B51. Journal of Virology, 2001, 75, 3984-3987.	1.5	30
112	IMMUNOPATHOGENESIS OF HEPATITIS B VIRUS INFECTION. Clinics in Liver Disease, 1999, 3, 221-239.	1.0	12
113	Recognition of a novel naturally processed, A2 restricted, HCV-NS4 epitope triggers IFN-gamma release in absence of detectable cytopathicity. Human Immunology, 1998, 59, 776-782.	1.2	27
114	Immunopathology of hepatitis C. Seminars in Immunopathology, 1997, 19, 57-68.	4.0	70
115	Association of Kidney Comorbidities and Acute Kidney Failure With Unfavorable Outcomes After COVID-19 in Individuals With the Sickle Cell Trait. JAMA Internal Medicine, 0, , .	2.6	15